Kala Bio Inc Reports Results For The Quarter Ended In June: Earnings Summary

KALA BIO

06/08/2024 15:20

* KALA BIO Inc  KALA.OQ  reported a quarterly adjusted loss
of
$3.16​​ per share for the quarter ended in June, higher than the
same quarter last year, when the company reported EPS of
$-4.36.  The mean expectation of two analysts for the quarter
was for a loss of $4.40 per share. Wall Street expected
results to range from $-4.58 to $-4.23 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * KALA BIO Inc's reported EPS for the quarter was a loss of
$3.16​.
    * The company reported a quarterly loss of $9.58 million.
    * KALA BIO Inc shares had fallen by 16.1% this quarter and
lost 15.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 54%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is  "buy."

Wall Street's median 12-month price target for KALA BIO Inc is
$16.50 
This summary was machine generated from LSEG data August 6 at
02:20 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -4.40          -3.16          Beat
 Mar. 31 2024      -2.89          -4.19          Missed
 Dec. 31 2023      -3.62          -3.18          Beat
 Sep. 30 2023      -2.15          -3.41          Missed